The Emerald Resources NL (ASX: EMR) share price was in focus on Wednesday after the company revealed a record full-year profit of $259.6 million, driven by higher gold prices and disciplined operations. Revenue jumped 40% to $612.3 million, as gold production from Okvau reached more than 100,000 ounces with costs among the lowest in the sector.

What did Emerald Resources report?

• Revenue: $612.3 million, up 40% from FY25
• Net profit after tax (NPAT): $259.6 million, up 196%
• EBITDA: $392.1 million, up 93% year on year
• Gold production: 100,405 ounces at an all-in sustaining cost (AISC) of US$972/oz
• Cash, bullion and investments: $491.1 million at 30 June 2026
• Dividends: No dividend declared for FY26

What else do investors need to know?

Emerald remained debt-free and unhedged, cementing its position as a low-cost gold producer. Operational highlights included expanding reserves and robust gold recoveries from the Okvau mine in Cambodia, now totalling over 509,600 ounces since production began in 2021. Growth activities ramped up across both Cambodia and Australia, supported by a strong balance sheet.

Beyond Okvau, significant progress was made on the Dingo Range and Memot projects. Both are fully permitted, with maiden ore reserve estimates to follow and studies well underway. Exploration continues to deliver promising results, leading to resource upgrades and demonstrating future growth pathways.

What’s next for Emerald Resources?

Looking ahead to FY27, Emerald expects gold production of 100,000–115,000 ounces at Okvau, with similar AISC guidance and the addition of new feed sources through further drilling. Development is progressing for both the Dingo Range (Western Australia) and Memot (Cambodia) projects, with definitive feasibility studies nearing completion and first mining activities on track for the coming year.

Exploration remains a priority, with over 3.9 million ounces now in global resources across key projects. Emerald continues to target becoming a multi-mine, 300,000–400,000 ounce per annum gold producer, backed by a solid cash position and expanding project pipeline.

Emerald Resources share price snapshot

The Emerald Resources share price has risen strongly in the past 12 months, smashing the S&P/ASX 200 index (ASX: XJO) with a gain of almost 85%.

View Original Announcement

The post Emerald Resources FY26 earnings: Record profit on gold price surge appeared first on The Motley Fool Australia.

More reading

• Emerald Resources delivers solid Q4 production and advances key projects

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Sigma Healthcare Ltd (ASX: SIG) share price is in focus today after the company reported a 15.5% lift in revenue to $10.8 billion and a 20.6% surge in normalised EBIT to $1.09 billion for FY26, its first full-year result since merging with Chemist Warehouse Group.

What did Sigma Healthcare report?

• Revenue: $10.8 billion, up 15.5% year on year
• Normalised EBIT: $1,090.0 million, up 20.6%, with margin rising to 10.1%
• Normalised NPAT: $732.3 million, up 22.3%
• Net debt reduced to $663 million (Debt to Normalised EBITDA: 0.57x)
• Integration synergies delivered: $32.6 million, aiming for $100 million p.a. by FY29
• Fully franked final dividend: 2.0 cents per share (full year: 4.0 cents per share)

What else do investors need to know?

Sigma’s Australian business remains its “engine room”, contributing $10.4 billion in revenue and $1,034.2 million in normalised EBIT. The international arm is gathering momentum, delivering 33% revenue growth and doubling EBIT, with Ireland now profitable and a push into the UK market underway.

Sigma added 24 Chemist Warehouse branded stores in Australia, reaching 561 stores, while opening 20 new international outlets. The company continued to expand its own and exclusive-label products, with annual sales near $1 billion and the Wagner Pharmaceuticals generic business growing over 30%.

What did Sigma Healthcare management say?

Sigma’s CEO, Vikesh Ramsunder, said:

FY26 demonstrates that Sigma is not simply larger after the merger, it is structurally stronger. Our highly scalable business model is underpinned by defensive industry characteristics. With the Australian infrastructure already in place and a clearly defined runway to keep growing, we are confident the model will keep compounding value.

What’s next for Sigma Healthcare?

Sigma’s FY27 agenda centres on growing its network, driving operating leverage, and boosting product differentiation. The company aims to open 13 new Chemist Warehouse stores in Australia and 19 internationally in the first half, including its entry into the UK. Refreshed growth in the Amcal and Discount Drug Stores brands is also expected, with 42 new Australian stores on the way.

With a capital-light model and a solid balance sheet, Sigma is targeting sustained growth and long-term shareholder value, with over half of planned synergy savings still to be realised.

Sigma Healthcare share price snapshot

The Sigma Healthcare share price has underperformed the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a decline of almost 7%.

View Original Announcement

The post Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth appeared first on The Motley Fool Australia.

More reading

• My top 5 ASX 200 shares to buy and hold
• Why I’d buy Coles, Telstra and this ASX 200 blue chip share for retirement
• ASX 200 technology and healthcare shares continued their comeback last week
• 3 ASX 200 blue-chip shares I’d buy now

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Bapcor Ltd (ASX: BAP) share price is in focus today after the company reported a statutory net loss of $431.6 million in FY26, driven mainly by non-cash impairment charges, while underlying EBITDA exceeded the top end of May’s guidance.

What did Bapcor report?

• Underlying revenue of $1,924.1 million, down 1.8% from FY25
• Statutory net loss after tax of $431.6 million, impacted by $442.4 million in post-tax significant items
• Underlying EBITDA of $152.5 million, exceeding guidance
• Underlying NPAT of $10.8 million, down 85.0% year-on-year
• Net bank debt reduced to $135.0 million from $364.8 million in FY25
• No final dividend declared to prioritise cash during the turnaround

What else do investors need to know?

Bapcor’s FY26 was a year of transition and turnaround, marked by the appointment of a new CEO, Chair, and strengthened leadership team. The second half saw improved operating momentum, with working capital initiatives delivering $68.5 million in cash flow and cash conversion rising sharply to 109.4%.

The company completed a $200 million equity raising in February 2026, helping to materially strengthen its balance sheet and reduce net debt. Bapcor also implemented cost and efficiency improvements, focusing on enhancing price competitiveness, stock availability, and customer engagement across its business units.

What did Bapcor management say?

Chief Executive Officer and Managing Director, Chris Wilesmith, said:

Since joining Bapcor in January, our priority has been restoring the fundamentals of the business. The actions implemented during the second half improved performance across the Group. Sales momentum improved across the Group through the final 5 months of the year, Networks returned to growth, Retail delivering positive like-for-like sales growth, and our working capital initiatives are delivering real value.

What’s next for Bapcor?

Looking ahead, Bapcor plans to build on its recent improvements with an ongoing turnaround program and a broader strategic review to clarify long-term priorities. The company is also considering divesting smaller, non-core assets to sharpen its focus on critical, high-return businesses.

In FY27, management expects modest revenue growth with trading momentum tipped to improve further. Early trading for the first six weeks shows sales slightly ahead of last year, although macroeconomic and geopolitical uncertainties persist. Profits are likely to be more heavily weighted to the second half of the year.

Bapcor share price snapshot

Over the past 12 months, the Bapcor share price has significantly underperformed the S&P/ASX 200 Index (ASX: XJO) with an 85% decline as operational challenges weighed on investor sentiment.

View Original Announcement

The post Bapcor Ltd FY26 earnings: turnaround gains, big impairment loss appeared first on The Motley Fool Australia.

More reading

• Bapcor reaffirms FY26 EBITDA guidance
• Down 84%, why Bapcor shares may have further to fall
• 3 ASX All Ords shares to sell this week: Experts

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.